Feasibility and efficacy of gemcitabine plus albumin-bound paclitaxel combination therapy (GEM+nabPTX therapy) in patients with borderline resectable pancreatic cancer in the neoadjvant setting.
Not Applicable
- Conditions
- Borderline resectable pancreatic cancer
- Registration Number
- JPRN-UMIN000022000
- Lead Sponsor
- Saitama Medical Center, Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) pulmonary fibrosis or interstitial pneumonitis 2) Active double cancer 3) Active infection 4) HBs antigen positive 5) patients are using flucytosine, phenytoin, warfarin 6) pregnant females, possibly pregnant females
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method R0 resection rate
- Secondary Outcome Measures
Name Time Method